Literature DB >> 12742604

The rule of rescue.

John McKie1, Jeff Richardson.   

Abstract

Jonsen coined the term "Rule of Rescue"(RR) to describe the imperative people feel to rescue identifiable individuals facing avoidable death. In this paper we attempt to draw a more detailed picture of the RR, identifying its conflict with cost-effectiveness analysis, the preference it entails for identifiable over statistical lives, the shock-horror response it elicits, the preference it entails for lifesaving over non-lifesaving measures, its extension to non-life-threatening conditions, and whether it is motivated by duty or sympathy. We also consider the measurement problems it raises, and argue that quantifying the RR would probably require a two-stage procedure. In the first stage the size of the individual utility gain from a health intervention would be assessed using a technique such as the Standard Gamble or the Time Trade-Off, and in the second the social benefits arising from the RR would be quantified employing the Person Trade-Off. We also consider the normative status of the RR. We argue that it can be defended from a utilitarian point of view, on the ground that rescues increase well-being by reinforcing people's belief that they live in a community that places great value upon life. However, utilitarianism has long been criticised for failing to take sufficient account of fairness, and the case is no different here: fairness requires that we do not discriminate between individuals on morally irrelevant grounds, whereas being "identifiable" does not seem to be a morally relevant ground for discrimination.

Entities:  

Keywords:  Analytical Approach; Health Care and Public Health

Mesh:

Year:  2003        PMID: 12742604     DOI: 10.1016/s0277-9536(02)00244-7

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  49 in total

1.  Policy alternatives for treatments for rare diseases.

Authors:  Abbas H Panju; Chaim M Bell
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

2.  Sliding Doors: should treatment of gender identity disorder and other body modifications be privately funded?

Authors:  Simona Giordano
Journal:  Med Health Care Philos       Date:  2012-02

Review 3.  Orphan drugs and the NHS: should we value rarity?

Authors:  Christopher McCabe; Karl Claxton; Aki Tsuchiya
Journal:  BMJ       Date:  2005-10-29

4.  Rationing of drugs for rare diseases.

Authors:  Dyfrig Hughes
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  How much will Herceptin really cost?

Authors:  Ann Barrett; Tom Roques; Matthew Small; Richard D Smith
Journal:  BMJ       Date:  2006-11-25

6.  Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.

Authors:  James W Dear; Pajaree Lilitkarntakul; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

7.  Doing 'Upstream' Priority-Setting for Global Health with Justice: Moving from Vision to Practice?

Authors:  Keith Syrett
Journal:  Public Health Ethics       Date:  2016-06-03       Impact factor: 1.940

Review 8.  Precisely Where Are We Going? Charting the New Terrain of Precision Prevention.

Authors:  Karen M Meagher; Michelle L McGowan; Richard A Settersten; Jennifer R Fishman; Eric T Juengst
Journal:  Annu Rev Genomics Hum Genet       Date:  2017-04-24       Impact factor: 8.929

9.  Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67.

Authors:  Arna S Desser; Dorte Gyrd-Hansen; Jan Abel Olsen; Sverre Grepperud; Ivar Sønbø Kristiansen
Journal:  BMJ       Date:  2010-09-22

10.  Recommendations for increasing the use of HIV/AIDS resource allocation models.

Authors:  Arielle Lasry; Anke Richter; Frithjof Lutscher
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.